Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Chief Scientific Officer to lead the Research & Development organization, bringing broad leadership experience, significant experience in drug development, and a deep understanding of the patient perspective as a treating oncologist. He previously served as a director on Bristol-Myer Squibb’s board from 2013-2017.

Tom has more than 30 years of medical, management, and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH). He served as Chairman and Chief Executive Officer of Massachusetts General Physicians Organization and as a member of the MGH board from 2015 to 2017.

Before his roles as Chairman and CEO at MGH, Tom served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Tom was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.

Tom is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Asked about his heritage, Tom said: “My Irish background is pretty solid. My father’s side came over in 1840s and mom’s side came over in the 1890’s. Neither ‘intermarried’ so my genetic stock is pretty much Irish. My Irish highlight is walking down High Street with my grandfather in Holyoke, MA, when he was the grand marshal of the St. Patrick’s Day Parade in 1965! I also had the chance to speak at the 300th anniversary of Trinity College Dublin – as a keynote speaker.” ♦